De novo CD5-positive diffuse large B-cell lymphoma of the temporal bone presenting with an external auditory canal tumor.
We report a 74-year-old woman with primary CD5-positive diffuse large B-cell lymphoma (DLBCL) of the temporal bone. The patient was admitted because of a mass in the left external auditory canal. She was treated with eight courses of CEOP therapy (rituximab was added from the sixth course) followed by radiotherapy of 40 Gy, and complete remission was achieved. The occurrence of malignant lymphoma in the temporal bone, which is an extremely unusual site, may have depended on the peculiarity of CD5-positive DLBCL.
Ogawa
Shoko
S
Department of Hematology, Mie University Graduate School of Medicine, Edobashi, Tsu.
Tawara
Isao
I
Ueno
Satoshi
S
Kimura
Miho
M
Miyazaki
Kana
K
Nishikawa
Hiroyoshi
H
Yamaguchi
Motoko
M
Kobayashi
Tohru
T
Shiku
Hiroshi
H
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology; D001859:Bone Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D018956:CD5 Antigens; D003520:Cyclophosphamide / Q000008:administration & dosage; D004424:Ear Canal; D004428:Ear Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D013701:Temporal Bone; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018956:CD5 Antigens; D015251:Epirubicin; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone